Trimethylamine N-oxide as a key microbial mediator in the progression of diabetic kidney disease

Abstract

In this editorial, we comment on the article by Song et al published in the recent issue of the World Journal of Nephrology, which investigates the mechanistic role of gut microbiota-derived trimethylamine N-oxide (TMAO) in accelerating diabetic kidney disease through renal fibrotic pathways. Diabetic kidney disease is increasingly recognised as a disorder influenced not only by intrinsic renal metabolic and inflammatory pathways. In the Zucker diabetic fatty model, the investigators demonstrate a reproducible pattern in which progression of renal injury is accompanied by distinct alterations in gut microbial composition and a marked rise in circulating TMAO concentrations. The incorporation of fecal microbiota transplantation further shows that the dysbiotic microbial environment characteristic of diabetic kidney disease possesses an intrinsically enhanced capacity to generate TMAO and can transfer this metabolic profile to recipient animals, establishing functional evidence that gut microbial changes can modify host metabolite production. Partial improvement in renal biochemical parameters, fibrotic protein expression, and histological abnormalities following inhibition of trimethylamine formation reinforces the mechanistic relevance of this pathway within the gut-kidney axis and supports the concept that therapeutic strategies targeting microbial metabolism may offer a promising direction for altering the clinical trajectory of diabetic kidney disease.

Key Words: Trimethylamine N-oxide; Diabetic kidney disease; Gut microbiota; Renal fibrosis; TGF-β/Smad signalling

Core Tip: Diabetic kidney disease is increasingly understood as a disorder shaped not only by metabolic and inflammatory injury but also by gut microbial dysbiosis that amplifies renal fibrotic signalling. Song et al demonstrate that trimethylamine N-oxide (TMAO), generated from microbial metabolism of dietary methylamines, functions as a potent upstream driver of transforming growth factor-β/Smad activation and tubulointerstitial fibrosis. Their use of fecal microbiota transplantation and microbial trimethylamine-inhibition provides compelling causal evidence linking dysbiosis, elevated TMAO, and renal injury. This editorial contextualizes these findings within emerging gut-kidney mechanisms and underscores the therapeutic potential of microbiota-targeted strategies in modifying the trajectory of diabetic kidney disease.

This editorial refers to “Gut microbiota-derived trimethylamine N-oxide exacerbates diabetic nephropathy by promoting renal fibrosis” by Song et al, 2025; https://dx.doi.org/10.5527/wjn.v14.i4.112066.

---

INTRODUCTION

In this editorial, we comment on the article by Song et al[1] published in the recent issue of World Journal of Nephrology. Diabetic kidney disease remains one of the most challenging and clinically consequential complications of diabetes, reflecting a complex interplay between metabolic disturbance, haemodynamic injury, inflammatory activation, and progressive structural remodelling within the kidney[1]. While longstanding models have emphasised hyperglycaemia, glomerular hypertension, and advanced glycation as primary drivers of renal decline, emerging evidence has broadened this view substantially. Increasing attention has been directed toward the gastrointestinal tract as an influential upstream organ system capable of shaping the biochemical, immunologic, and redox environment in which diabetic kidney injury unfolds[2]. Disturbances in gut microbial composition, increased intestinal permeability, altered fermentation pathways, and dysregulated microbial metabolite production have all been implicated as contributors to the molecular milieu that promotes tubular stress, endothelial dysfunction, and interstitial fibrosis in diabetes[3].

Within this expanding field, the microbial-derived metabolite trimethylamine-N-oxide (TMAO) has gained particular prominence. Once regarded as a passive correlate of metabolic dysregulation, TMAO is now recognised as a biologically active signalling molecule capable of modulating oxidative stress responses, impairing mitochondrial homeostasis, enhancing inflammatory cytokine production, and amplifying profibrotic pathways. Its generation through the microbial conversion of dietary methylamines, followed by hepatic oxidation, forms a metabolic axis that links nutritional exposures and microbial ecology with renal cellular behaviour in a highly specific and mechanistically coherent manner. Accumulating experimental and translational data indicate that elevated TMAO is closely associated with heightened transforming growth factor-beta (TGF-β) activity, increased Smad phosphorylation, and exaggerated extracellular matrix deposition-processes central to the progression of diabetic kidney disease[4,5].

Recent work by Song et al[1] provides a compelling demonstration of this mechanistic relationship, showing that higher TMAO exposure intensifies canonical TGF-β/Smad signalling and accelerates tubulointerstitial fibrosis in a well-characterised model of diabetic renal injury. Their findings build upon earlier observations that microbial dysbiosis and metabolite derangements are closely integrated with the inflammatory and redox disturbances typical of diabetes, offering direct experimental confirmation that TMAO is not merely an epiphenomenon of metabolic imbalance but a proximal biochemical effector of renal fibrosis.

This editorial synthesises insights spanning microbial ecology, metabolite biology, renal immunoinflammation, oxidative stress physiology, and global diabetes epidemiology to contextualise the emerging significance of TMAO in diabetic kidney disease. Taken together, current evidence suggests that TMAO represents a biologically plausible, mechanistically integrated, and potentially modifiable driver of renal fibrosis-highlighting the growing relevance of gut-derived metabolic pathways in shaping the natural history of diabetic kidney disease[2-5].

DYSBIOTIC MICROBIAL ARCHITECTURE AS THE UPSTREAM SOURCE OF TMAO BURDEN

Microbial disruption in diabetes: A metabolic organ in disequilibrium

Diabetes exerts a profound and progressive influence on gut microbial organisation, transforming the intestine from a stable ecological community into a metabolically disordered environment with direct systemic consequences. The disruption is characterised primarily by a marked reduction in short-chain-fatty-acid-producing commensals such as Faecalibacterium prausnitzii and Lachnospira, organisms that normally support epithelial integrity, regulate inflammatory tone, and contribute to metabolic homeostasis. Their loss removes a central anti-inflammatory buffering system within the gut, thereby exposing the mucosa to greater vulnerability from luminal stressors. At the same time, there is a notable expansion of gram-negative, facultative anaerobic taxa capable of generating both endotoxins and trimethylamine (TMA), the obligate microbial precursor required for hepatic conversion into trimethylamine-N-oxide (TMAO). This re-organisation of microbial communities represents more than a compositional shift; it reflects a fundamental disturbance in luminal metabolic programming, with important implications for renal injury in diabetes[4,5].

Accompanying these microbial alterations is a measurable weakening of intestinal barrier architecture. Diabetes is consistently associated with impaired tight-junction integrity, increased epithelial permeability, and heightened exposure of the host immune system to microbial products that would ordinarily remain compartmentalised within the gut lumen. As this barrier dysfunction progresses, the systemic absorption of microbially derived metabolites increases, permitting higher circulating levels of TMA and facilitating greater hepatic generation of TMAO. This sequence creates a direct and biologically coherent bridge between microbial dysbiosis and systemic metabolic injury[6].

The resulting microbial milieu is defined by several recurring features: Enrichment of Proteobacteria, Enterobacteriaceae, and Escherichia spp., taxa that favour proteolytic metabolism and possess the enzymatic machinery required for TMA formation. Loss of short-chain fatty acid -producing genera, removing critical butyrate-mediated anti-inflammatory pathways that ordinarily constrain oxidative and immune activation. Upregulation of TMA lyase pathways, enabling greater efficiency in microbial conversion of dietary methylamines to TMA. Leakage of outer-membrane-vesicle -derived lipopolysaccharide, which further undermines epithelial stability and promotes systemic inflammatory readiness[7,8].

Together, these disturbances establish a microbial ecosystem that is primed to generate a disproportionately high TMA burden and to accelerate TMAO exposure. This dysbiotic, metabolically permissive environment forms the upstream architecture that connects intestinal imbalance to renal fibrogenic signalling in diabetes[7]. The principal microbial-metabolic disturbances underpinning this dysbiotic state are summarised in Table 1.

Table 1 Microbial-metabolic disturbances that promote trimethylamine N-oxide -driven pathways in diabetic kidney disease[4-8].

Pathway	Microbial derangement	Physiological consequence	Relevance to TMAO biology
Outer-membrane-vesicle-associated LPS production	Increase in gram-negative organisms	Activation of TLR4, NF-κB, and NLRP3 pathways	Enhances renal responsiveness to TGF-β-mediated fibrotic signalling
Depletion of short-chain-fatty-acid-producing taxa	Reduction in Faecalibacterium prausnitzii and Lachnospira	Loss of GPR43 and GPR109A anti-inflammatory signalling	Diminishes intrinsic anti-fibrotic buffering and lowers resistance to TMAO-driven injury
Enhanced microbial trimethylamine formation	Expansion of TMA-generating microbial communities	Increased luminal TMA availability	Greater hepatic conversion of TMA to TMAO, elevating systemic TMAO burden
Impaired intestinal barrier integrity	Reduced expression of ZO-1 and occludin	Increased translocation of microbial products into systemic circulation	Augments systemic inflammatory activation and magnifies TMAO-associated renal effects

LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; NLRP3: NOD-like receptor family pyrin domain containing 3; TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide; ZO-1: Zonula occludens-1.

TMAO AS A MOLECULAR AMPLIFIER: CONVERGENCE ON TGF-Β/SMAD FIBROTIC SIGNALLING

Endothelial and inflammatory activation

TMAO exerts powerful modulatory effects on endothelial behaviour and inflammatory readiness, and these actions acquire particular significance in the diabetic kidney, where underlying metabolic stress has already compromised vascular and tubular resilience. TMAO has been shown to upregulate the expression of adhesion molecules such as VCAM-1, promoting enhanced monocyte attachment and facilitating early leukocyte recruitment into renal tissue. In parallel, it activates nuclear factor-κB signalling, a central transcriptional regulator that coordinates the production of pro-inflammatory mediators including tumour necrosis factor-α, interleukin-1β, and monocyte chemoattractant protein-1. In a diabetic milieu-characterised by advanced glycation, endothelial stiffening, and microvascular fragility-these TMAO-driven events intensify the inflammatory tone of the renal microenvironment. The combined effect is a state in which glomerular and tubular compartments are primed for heightened susceptibility to downstream fibrotic triggers, particularly those mediated through the TGF-β/Smad pathway[7,8].

Mitochondrial redox disruption

A second, equally important dimension of TMAO biology relates to its capacity to perturb mitochondrial homeostasis. Experimental data consistently demonstrate that TMAO increases mitochondrial reactive oxygen species production and promotes the activation of the mROS-NLRP3 inflammatory axis. The consequences of this redox imbalance extend well beyond oxidative stress; increased reactive oxygen species (ROS) generation lowers the activation threshold for TGF-β-driven Smad phosphorylation, thereby facilitating the transition from reversible cellular injury to irreversible fibrotic remodelling. This effect is particularly pronounced in diabetic kidneys, which exist in a chronically pre-oxidised state due to metabolic overload, impaired antioxidant defences, and ongoing glycation-induced mitochondrial dysfunction. In such a setting, TMAO does not act as a primary initiator of oxidative injury but rather as a potent amplifier, superimposing an additional oxidative burden that accelerates fibrogenic transformation within tubular epithelial cells and interstitial fibroblasts[8,9].

Cell-specific renal targets of TMAO

Beyond its global fibrotic effects, TMAO exerts distinct pathogenic actions on individual renal cell populations. In podocytes, TMAO promotes mitochondrial stress, cytoskeletal instability, and disruption of slit-diaphragm integrity, thereby accelerating albumin leakage and glomerular injury. In mesangial cells, TMAO enhances TGF-β1-driven matrix production, contributing to mesangial expansion and glomerulosclerosis. In renal tubular epithelial cells, TMAO induces kidney injury molecule-1 (KIM-1) expression, mitochondrial reactive oxygen species generation, and Smad3 phosphorylation, driving epithelial-mesenchymal transition and interstitial fibrogenesis. In parallel, interstitial fibroblasts exposed to TMAO demonstrate increased α-smooth muscle actin expression and collagen synthesis, collectively orchestrating progressive tubulointerstitial fibrosis in diabetic kidney disease[7-10].

Accumulation within renal parenchyma

As diabetic kidney disease progresses and glomerular filtration rate declines, the kidney’s capacity to clear circulating TMAO diminishes. This reduction in renal excretion allows progressive intrarenal accumulation of TMAO, enabling the metabolite to reach concentrations capable of influencing intracellular signalling. TMAO readily penetrates renal parenchymal compartments, and sustained exposure at these elevated tissue levels provides a continuous stimulus for redox imbalance, endothelial activation, and TGF-β/Smad pathway amplification. In this context, TMAO behaves not merely as a circulating marker of microbial dysbiosis but as a direct biochemical participant in renal structural injury. Its progressive accumulation ensures that once the fibrotic cascade is initiated, the kidney remains under persistent metabolic pressure that reinforces and perpetuates the fibrogenic trajectory characteristic of diabetic kidney disease[1,10]. The integrated positioning of TMAO within the gut-kidney signalling axis is depicted in Figure 1.

Figure 1 Pathogenic Integration of trimethylamine N-oxide within the gut-kidney signalling axis. This figure illustrates how dysbiotic gut microbiota enhance trimethylamine production, driving hepatic conversion to trimethylamine N-oxide (TMAO). Elevated systemic TMAO amplifies endothelial activation, oxidative stress, and transforming growth factor-beta/Smad signalling within renal tissue, promoting tubulointerstitial fibrosis. Progressive decline in kidney function further increases TMAO accumulation, creating a self-reinforcing cycle of microbial dysbiosis, metabolic disturbance, and fibrogenic injury along the gut-kidney axis. TMAO: Trimethylamine N-oxide; TMA: Trimethylamine; ROS: Reactive oxygen species; TNF-α: Tumor necrosis factor-alpha; IL-1β: Interleukin-1beta; MCP-1: Monocyte chemoattractant protein-1; TGF-β: Transforming growth factor-beta.

GLOBAL EPIDEMIOLOGY: WHY TMAO HAS BECOME INCREASINGLY RELEVANT

The evolving global epidemiology of diabetes provides an essential backdrop for understanding why microbial metabolites such as TMAO have gained increasing pathogenic relevance in recent years. According to projections from the International Diabetes Federation, the number of adults living with diabetes is expected to rise from 415 million in 2015 to 642 million by 2040, with the steepest increases occurring in low- and middle-income regions. This expansion reflects not only demographic growth but profound alterations in lifestyle, diet, and environmental exposures that together reshape the metabolic and microbial landscape in which diabetic kidney disease develops. Of particular importance is the rapid westernisation of dietary patterns, characterised by greater consumption of foods rich in choline and carnitine-substrates that drive the microbial formation of trimethylamine, the precursor of TMAO[11,12].

Parallel changes have further amplified this shift. Increasing antibiotic exposure and sanitation-driven modifications in microbial ecology have altered the diversity and stability of gut communities, often favouring taxa capable of producing TMA. Modern food systems dominated by processed products and markedly reduced fibre intake have further weakened the ecological resilience of the intestinal microbiota, diminishing populations of commensal organisms that normally confer metabolic protection. Compounding these pressures is the exceptionally high proportion of individuals with undiagnosed diabetes, particularly in regions undergoing rapid economic and nutritional transition. In these settings, renal injury often begins before glycaemic control is established, and the metabolic consequences of dysbiosis exert disproportionate influence on disease progression[13].

Taken together, these global trends have produced a metabolic ecosystem in which the pathways governing TMA formation and TMAO accumulation are consistently activated. As a result, the biological behaviour of diabetic kidney disease is increasingly shaped by microbial-metabolite interactions that were less prominent in earlier epidemiological eras. Global nutritional modernisation has therefore created conditions under which TMAO assumes heightened mechanistic relevance, reinforcing its importance as a contributor to the natural history of diabetic kidney disease[12,13]. Key global epidemiologic trends that intensify activation of the TMA-TMAO axis are outlined in Table 2.

Table 2 Global diabetes trends that intensify trimethylamine N-oxide -associated fibrotic pathways[2,11-13].

Epidemiologic trend	Underlying biological mechanism	Implication for the TMAO pathway
Increasing consumption of processed foods	Higher dietary intake of choline and carnitine	Greater availability of substrates for microbial trimethylamine formation
Rapid urbanisation	Westernisation of gut microbial composition	Expansion of microbial taxa capable of producing TMA
High proportion of undiagnosed diabetes	Delayed identification of renal injury and prolonged metabolic stress	Increased susceptibility of the kidney to TMAO-mediated fibrotic responses
Rising diabetes prevalence in low- and middle-income regions	Nutritional transition with reduced fibre intake and altered microbial ecology	Amplification of dysbiosis favouring TMA-generating microbiota
Increasing premature mortality in diabetes	Heightened oxidative and inflammatory burden	Lowered threshold for TMAO-driven ROS generation and Smad activation

TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide; ROS: Reactive oxygen species.

CLINICAL AND EXPERIMENTAL EVIDENCE SUPPORTING TMAO AS A CAUSAL MEDIATOR

Human prognostic data

Clinical observations provide important support for the pathogenic relevance of TMAO in renal disease. In a large cohort of more than 3600 adults, individuals with impaired kidney function were found to have approximately twice the circulating concentration of TMAO compared with those with preserved renal function. Notably, participants in the highest quartile of TMAO levels experienced nearly a three-fold increase in five-year mortality, and this association persisted even after rigorous adjustment for diabetes status, systemic inflammation, traditional cardiovascular risk factors, and baseline kidney function. Such independence from established confounders strengthens the likelihood that TMAO contributes directly to biological processes influencing long-term outcomes, rather than merely reflecting secondary metabolic disturbances that accompany chronic illness. The prognostic separation observed across TMAO strata underscores its potential role as an active mediator of renal and systemic injury[10,14].

Direct experimental demonstration of fibrosis

Experimental models provide complementary mechanistic clarity. Chronic exposure to diets enriched with TMAO or its metabolic precursors consistently induces changes that mirror the structural and signalling abnormalities characteristic of diabetic kidney disease. Animals receiving such diets develop marked tubulointerstitial collagen deposition, indicating accelerated matrix accumulation within renal parenchyma. These structural changes are accompanied by increased phosphorylation of Smad3, a central effector within the TGF-β signalling cascade, confirming activation of canonical profibrotic pathways[9,15].

Further evidence of injury is reflected in the upregulation of KIM-1, a sensitive marker of tubular epithelial stress, and in elevations of serum cystatin C, which signal functional impairment. The convergence of these biochemical, histological, and functional findings provides strong experimental support for the view that TMAO is capable of directly promoting renal fibrogenesis. Importantly, the pattern of injury observed aligns closely with the well-described structural trajectory of diabetic kidney disease, reinforcing the notion that TMAO participates in the same molecular networks that drive disease progression[9,10,15].

THERAPEUTIC MODULATION OF THE TMAO PATHWAY: MICROBIAL ENZYME INHIBITION

A pivotal therapeutic advance emerges from the observation that 3,3-dimethyl-1-butanol (DMB) can inhibit microbial TMA lyases while preserving bacterial viability, establishing a new class of microbiota-directed, non-antibiotic metabolic interventions. By blocking TMA formation at its origin, DMB reduces circulating TMAO levels without disturbing overall microbial ecology and prevents the oxidative, inflammatory, and fibrotic responses typically associated with TMAO exposure. Across both diet-induced and diabetic models, this approach leads to meaningful attenuation of renal injury, reflected in reduced oxidative stress, diminished cytokine activation, and suppression of collagen accumulation and Smad signalling[14,15]. The principal mechanistic and therapeutic insights arising from microbial TMA inhibition are summarised in Table 3.

Table 3 Mechanistic and therapeutic insights derived from microbial trimethylamine inhibition[10,14,15].

DMB observation	Mechanistic insight	Relevance to diabetic kidney disease
Inhibition of CutC/D TMA lyases	Proximal blockade of microbial TMA formation	Lowers the upstream substrate load driving TMAO accumulation
Demonstrated activity in human fecal cultures	Effective within complex microbial ecosystems	Applicable even in dysbiotic communities characteristic of diabetes
No observed hepatic, renal, or metabolic toxicity	Preserves physiological homeostasis	Suitable for long-term use in chronic disease settings
Reduction of TMA-producing taxa	Favourable restructuring of gut microbial composition	Addresses dysbiosis that contributes to DN severity
Prevention of fibrotic signalling	Decreases NOX4, pro-inflammatory cytokines, and Smad activation	Slows the trajectory of diabetic kidney injury

DMB: 3,3-dimethyl-1-butanol; CutC/D: Choline trimethylamine lyase enzyme complex; TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide; NOX4: NADPH oxidase-4; DN: Diabetic nephropathy; DKD: Diabetic kidney disease.

OBESITY MODELS DEMONSTRATE HYPERGLYCAEMIA-INDEPENDENT TMAO TOXICITY

Evidence from high-fat diet models provides an important complement to diabetic studies by showing that TMAO-driven renal injury is not contingent on hyperglycaemia. Dietary fat loading leads to a marked rise in circulating TMAO, accompanied by upregulation of KIM-1, NOX4-mediated oxidative stress, activation of tumor necrosis factor-alpha and interleukin-1beta, phosphorylation of Smad3, and progressive interstitial fibrosis. Notably, each of these abnormalities is reversed by microbial inhibition of TMA formation, demonstrating that the renal injury sequence is metabolically transmissible and TMAO-dependent. These findings confirm that TMAO possesses intrinsic fibrogenic capacity even in the absence of diabetes[9,13,15].

GUT BARRIER DYSFUNCTION IN CKD: ESTABLISHING THE ABSORPTIVE GATEWAY FOR TMAO

Chronic kidney disease produces a profoundly altered gut environment that directly increases systemic exposure to microbial metabolites. The influx of urea and its conversion to ammonia elevate luminal pH, disrupt epithelial integrity, and promote the loss of commensal short-chain-fatty-acid-producing organisms. This ecological shift favours the expansion of proteolytic and urease-rich taxa while simultaneously degrading key tight-junction proteins, including claudin-1, occludin, and zonula occludens-1. The resulting barrier breakdown markedly enhances the absorption of TMA and related bacterial products into the circulation. Because diabetic kidney disease commonly coexists with dysbiosis, this chronic kidney disease -associated defect in gut permeability further amplifies the systemic TMAO burden[6,16].

ESTABLISHING CAUSALITY: CORE MECHANISTIC INSIGHTS INTO TMAO-DRIVEN DIABETIC KIDNEY DISEASE

A growing body of mechanistic evidence now demonstrates with exceptional clarity that TMAO is not merely an associative biomarker but a direct pathogenic mediator in diabetic kidney disease. The experimental framework underpinning this insight brings coherence to previously disparate observations and defines a causal sequence linking microbial dysbiosis, metabolic perturbation, and renal fibrogenesis[14,16-18]. These mechanistic foundations can be articulated through five interdependent pillars:

Diabetes induces a TMA-producing dysbiotic state

Diabetes reshapes gut microbial composition toward taxa with enhanced capacity to generate trimethylamine, resulting in steadily rising systemic TMAO levels even before overt decline in renal function becomes apparent[19,20].

TMAO activates canonical fibrotic pathways

Renal exposure to TMAO leads to upregulation of TGF-β1, phosphorylation of Smad2 and Smad3, increased α-smooth muscle actin, and expansion of interstitial collagen-constituting the core signalling architecture of kidney fibrosis[21,22].

Oxidative stress amplifies the fibrogenic response

The diabetic kidney exhibits marked susceptibility to redox perturbation, and TMAO further intensifies this vulnerability through NOX4 induction, ROS accumulation, and lipid peroxidation. This oxidative environment lowers the threshold for fibrosis initiation and progression[23,24].

Microbiota transplantation transfers the TMAO-fibrosis phenotype

Transfer of diabetic microbiota to healthy recipients reproduces elevated TMAO levels and initiates early renal injury, demonstrating that microbial composition alone can transmit the profibrotic metabolic programme, independent of glycaemic status[25,26].

Inhibiting microbial TMA formation reverses renal injury

Pharmacological suppression of TMA generation reduces circulating TMAO and attenuates structural and molecular markers of fibrosis, providing direct translational evidence that the TMA-TMAO axis is a modifiable driver of diabetic kidney disease[27-30]. The central experimental components defining the fibrotic identity of TMAO are consolidated in Table 4.

Table 4 Central experimental insights defining the fibrotic role of trimethylamine-N-oxide[1,9,10,15,17].

Experimental component	Key observation	Interpretation
Microbial profiling	Increase in TMA-producing taxa in diabetic animals	Dysbiosis acts as the initiating metabolic trigger
Plasma TMAO levels	Progressive rise during disease evolution	Represents an early and persistent metabolic signature
Microbiota transplantation	Non-diabetic recipients develop renal injury and fibrosis	Demonstrates microbiota-mediated transmission of pathogenic signals
Fibrotic markers	Upregulation of TGF-β1, Smad2/3, and α-SMA	Indicates direct activation of canonical profibrotic pathways
Inhibition of TMA formation	Reversal of structural and biochemical injury	Confirms causal and therapeutically reversible role of the TMAO-driven fibrotic pathway

TMAO: Trimethylamine-N-oxide; α-SMA: Alpha-smooth muscle actin; TGF-β: Transforming growth factor-beta.

SYNTHESIS: TMAO AS AN ACTIONABLE METABOLIC DRIVER OF DIABETIC KIDNEY DISEASE

The collective body of evidence spanning microbial ecology, systemic metabolism, endothelial activation, oxidative injury, experimental fibrosis, and global nutritional change converges on a single integrated pathway. Dysbiosis increases microbial production of trimethylamine, which is subsequently oxidised by hepatic FMO3 to yield circulating TMAO. As renal function becomes impaired, TMAO accumulates within the kidney, where it triggers a cascade of TGF-β/Smad signalling, endothelial activation, and redox imbalance that accelerates interstitial fibrosis. Crucially, inhibition of microbial TMA formation interrupts this sequence and prevents structural and biochemical injury[9,12,14,15,29,30]. Taken together, these observations define TMAO as one of the few gut-derived metabolites for which the entire pathogenic arc-from microbial origin to intracellular signalling to therapeutic reversal-is clearly delineated.

Importantly, the TMAO pathway operates upstream of conventional therapeutic targets in diabetic kidney disease. While renin-angiotensin-aldosterone system inhibitors attenuate intraglomerular pressure and suppress downstream TGF-β signalling, and sodium-glucose cotransporter-2 inhibitors reduce oxidative stress and improve tubular metabolism, neither directly addresses microbial trimethylamine generation or hepatic TMAO production. Microbiota-targeted strategies therefore represent a complementary and potentially synergistic axis of disease modification, capable of suppressing the metabolic root of TMAO-driven fibrogenesis rather than only its renal consequences[15,17,31,32].

Future clinical research should now move beyond association toward validation and intervention. Prospective cohort studies evaluating circulating TMAO as a prognostic biomarker in diabetic kidney disease, and randomized trials testing microbial TMA-suppression, dietary substrate restriction, or microbiota-modifying therapies, are urgently needed to determine whether modulation of the gut-kidney metabolic axis can meaningfully alter renal outcomes[14-17,28-32].

CONCLUSION

A contemporary understanding of diabetic kidney disease must account for the upstream metabolic forces exerted by the gut microbiota. Among the diverse spectrum of microbial metabolites implicated in renal injury, TMAO stands apart for the consistency and coherence of its supporting evidence across epidemiologic, mechanistic, and interventional domains. Its capacity to function as a direct effector molecule-amplifying TGF-β/Smad signalling, intensifying oxidative injury, and accelerating collagen deposition-signals a fundamental shift in how the pathogenesis of diabetic kidney disease is conceptualised. The intersection of global epidemiology, microbial dysbiosis, cellular signalling, and therapeutic feasibility supports a unified and compelling conclusion: TMAO is not a passive byproduct of metabolic dysfunction but an actionable driver of renal fibrogenesis in diabetes. Recognising this metabolic axis opens a new translational landscape in which microbiota-directed interventions may finally offer a disease-modifying avenue for one of the most common and progressive complications of the global diabetes epidemic.